Correlation Between Sellas Life and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sellas Life and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sellas Life and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sellas Life Sciences and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Sellas Life and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sellas Life with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sellas Life and Reviva Pharmaceuticals.

Diversification Opportunities for Sellas Life and Reviva Pharmaceuticals

0.11
  Correlation Coefficient

Average diversification

The 3 months correlation between Sellas and Reviva is 0.11. Overlapping area represents the amount of risk that can be diversified away by holding Sellas Life Sciences and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Sellas Life is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sellas Life Sciences are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Sellas Life i.e., Sellas Life and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Sellas Life and Reviva Pharmaceuticals

Considering the 90-day investment horizon Sellas Life Sciences is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Sellas Life Sciences is 2.22 times less risky than Reviva Pharmaceuticals. The stock trades about -0.02 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  124.00  in Reviva Pharmaceuticals Holdings on August 31, 2024 and sell it today you would lose (10.00) from holding Reviva Pharmaceuticals Holdings or give up 8.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Sellas Life Sciences  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Sellas Life Sciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sellas Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Sellas Life is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong basic indicators, Reviva Pharmaceuticals is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.

Sellas Life and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sellas Life and Reviva Pharmaceuticals

The main advantage of trading using opposite Sellas Life and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sellas Life position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Sellas Life Sciences and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements